Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
uniQure
Pharma
After Hemgenix approvals, uniQure inks $400M sale of royalties
Months after the first approvals of its CSL-partnered hemophilia A gene therapy, uniQure is selling some royalty rights for up to $400 million.
Zoey Becker
May 15, 2023 3:10pm
New CEO Paul McKenzie plots CSL's course for growth
Apr 3, 2023 9:25am
CSL's hemophilia B gene therapy works well through 24 months
Dec 12, 2022 2:14pm
'The Top Line': Biogen's new CEO, plus this week's headlines
Dec 2, 2022 8:34am
Costing $3.5M, first hemophilia B gene therapy wins FDA approval
Nov 23, 2022 10:42am
2022 forecast: Cell, gene therapy makers have high hopes
Dec 22, 2021 3:00am